Integra Therapeutics secures €10.7 Million Investment Round to Advance Development of FiCAT Gene Writing Platform and Preclinical Validation of CAR-T Therapies

Integra Therapeutics, a global leader in cutting-edge gene writing tools to improve the efficacy, led by Avencia Sánchez-Mejíasa and Marc Güell, has raised €10.7 million pre Series A round of investment from EIC Fund, with the European Investment Bank (EIB) as the investor of record, which invested €4 million, and CDTI Innvierte of the Spanish Ministry of Science, Innovation and University, which contributed €2.7 million, as well as from existing investors AdBio Partners, Columbus Venture Partners, Invivo Partners and Takeda Ventures, which continue to support the company’s vision.

Funds will advance the FiCAT gene writing platform, support preclinical validation of next-gen CAR-T therapies, and expand cell engineering capabilities for pharma partnerships. In May, FiCAT reported promising new preclinical data at ASGCT 2025.

CEO Avencia Sánchez-Mejías says the funding will help Integra advance innovation in cell and gene therapies, bringing transformative treatments for cancer, autoimmune, and rare diseases closer to reality.

Svetoslava Georgieva, Chair of the EIC Fund Board, says the investment will help Integra accelerate breakthrough therapies with the potential to transform lives and advance gene therapy globally.